Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 2
2005 1
2007 2
2008 3
2009 2
2010 2
2011 5
2012 3
2013 10
2014 7
2015 3
2016 8
2017 14
2018 6
2019 9
2020 15
2021 16
2022 6
2023 13
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

109 results

Results by year

Filters applied: . Clear all
Page 1
The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations and their influence on the NLR in NSCLC patients treated with immunotherapy.
Proulx-Rocray F, Routy B, Nassabein R, Belkaid W, Tran-Thanh D, Malo J, Tonneau M, Ouarzadi OE, Florescu M, Tehfe M, Blais N. Proulx-Rocray F, et al. Among authors: blais n. Cancer Treat Res Commun. 2023;37:100767. doi: 10.1016/j.ctarc.2023.100767. Epub 2023 Oct 10. Cancer Treat Res Commun. 2023. PMID: 37832364 Free article.
Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience.
Rupp M, Fanton-Aita F, Snow S, Wheatley-Price P, Melosky B, Juergens RA, Chu Q, Blais N, Banerji S, Ng R, Khoudigian S, Sharma A, On PV, Liu G. Rupp M, et al. Among authors: blais n. Curr Oncol. 2023 Jul 8;30(7):6559-6574. doi: 10.3390/curroncol30070481. Curr Oncol. 2023. PMID: 37504341 Free PMC article.
Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC.
Cheema PK, Banerji SO, Blais N, Chu QS, Juergens RA, Leighl NB, Sacher A, Sheffield BS, Snow S, Vincent M, Wheatley-Price PF, Yip S, Melosky BL. Cheema PK, et al. Among authors: blais n. Curr Oncol. 2023 Jul 6;30(7):6473-6496. doi: 10.3390/curroncol30070476. Curr Oncol. 2023. PMID: 37504336 Free PMC article.
Phase II multicenter trial combining nivolumab and radiosurgery for NSCLC and RCC brain metastases.
Wong P, Masucci L, Florescu M, Plourde ME, Panet-Raymond V, Pavic M, Owen S, Masson-Coté L, Ménard C, Routy B, Tehfe M, Nelson K, Guilbert F, Boucher O, Keshavarzi S, Blais N, Roberge D. Wong P, et al. Among authors: blais n. Neurooncol Adv. 2023 Mar 1;5(1):vdad018. doi: 10.1093/noajnl/vdad018. eCollection 2023 Jan-Dec. Neurooncol Adv. 2023. PMID: 37025758 Free PMC article.
109 results